In addition, these findings confirm the expected ability of mutant RAS to render EGFR-mutant adenocarcinoma cells resistant to TKI's and further enhance the significance of not observing oncogenic KRAS mutations in human tumors resistant to erlotinib (Ohashi et al., 2012) (see ‘Discussion’). Here, EGFR is linked to adenocarcinoma.